Synthetic high-density lipoprotein-like nanoparticles for cancer therapy

References

• Cruz PM, Mo H, McConathy WJ, et al. The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics. Front Pharmacol 2013;4:119
   PubMed Web of Science ®Google Scholar
• Gorin A, Gabitova L, Astsaturov I. Regulation of cholesterol biosynthesis and cancer signaling. Curr Opin Pharmacol 2012;12(6):710-16
   PubMed Web of Science ®Google Scholar
• Brown AJ. Cholesterol, statins and cancer. Clin Exp Pharmacol P 2007;34(3):135-41
   PubMed Web of Science ®Google Scholar
• Simons K, Ikonen E. How cells handle cholesterol. Science 2000;290(5497):1721-6
   PubMed Web of Science ®Google Scholar
• Simons K, Gerl MJ. Revitalizing membrane rafts: new tools and insights. Nat Rev Mol Cell Bio 2010;11(10):688-99
   PubMedGoogle Scholar
• Clendening JW, Pandyra A, Boutros PC, et al. Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci USA 2010;107(34):15051-6
   PubMed Web of Science ®Google Scholar
• Ginestier C, Monville F, Wicinski J, et al. Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. Stem Cells 2012;30(7):1327-37
   PubMedGoogle Scholar
• Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232(4746):34-47
   PubMed Web of Science ®Google Scholar
• Olson RE. Discovery of the lipoproteins, their role in fat transport and their significance as risk factors. J Nutr 1998;128(2):439s-43s
   PubMedGoogle Scholar
• Chapman MJ. Animal lipoproteins: chemistry, structure, and comparative aspects. J Lipid Res 1980;21(7):789-853
   PubMed Web of Science ®Google Scholar
• Fiorenza AM, Branchi A, Sommariva D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res 2000;30(3):141-5
   PubMedGoogle Scholar
• Mehta R, Gurudath S, Dayansoor S, et al. Serum lipid profile in patients with oral cancer and oral precancerous conditions. Dental Res J 2014;11(3):345-50
   PubMedGoogle Scholar
• Muntoni S, Atzori L, Mereu R, et al. Serum lipoproteins and cancer. Nutrition Metabol Cardiovasc Dis 2009;19(3):218-25
   PubMedGoogle Scholar
• Niendorf A, Nagele H, Gerding D, et al. Increased LDL receptor mRNA expression in colon cancer is correlated with a rise in plasma cholesterol levels after curative surgery. Int J Cancer 1995;61(4):461-4
   PubMed Web of Science ®Google Scholar
• Leon CG, Locke JA, Adomat HH, et al. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 2010;70(4):390-400
   PubMed Web of Science ®Google Scholar
• Shahzad MMK, Mangala LS, Han HD, et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 2011;13(4):309-U142
   PubMed Web of Science ®Google Scholar
• Llaverias G, Danilo C, Mercier I, et al. Role of cholesterol in the development and progression of breast cancer. Am J Pathol 2011;178(1):402-12
   PubMed Web of Science ®Google Scholar
• Danilo C, Gutierrez-Pajares JL, Mainieri MA, et al. Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development. Breast Cancer Res 2013;15(5):R87
   PubMedGoogle Scholar
• Rotheneder M, Kostner GM. Effects of low- and high-density lipoproteins on the proliferation of human breast cancer cells in vitro: differences between hormone-dependent and hormone-independent cell lines. Int J Cancer 1989;43(5):875-9
   PubMedGoogle Scholar
• Uda S, Accossu S, Spolitu S, et al. A lipoprotein source of cholesteryl esters is essential for proliferation of CEM-CCRF lymphoblastic cell line. Tumour Biol 2012;33(2):443-53
   PubMedGoogle Scholar
• Danilo C, Frank PG. Cholesterol and breast cancer development. Curr Opin Pharmacol 2012;12(6):677-82
   PubMed Web of Science ®Google Scholar
• Navab M, Reddy ST, Van Lenten BJ, et al. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009;50(Suppl):S145-9
   PubMedGoogle Scholar
• Eren E, Yilmaz N, Aydin O. High density lipoprotein and it’s dysfunction. Open Biochem J 2012;6:78-93
   PubMedGoogle Scholar
• Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nature Cell Biol 2011;13(4):423-33
   PubMed Web of Science ®Google Scholar
• Vickers KC, Remaley AT. Functional diversity of HDL cargo. J Lipid Res 2013; R035964
   Google Scholar
• Jonas A, Phillips MC. Lipoprotein structure. N Comp Bioc 2008;485-506
   Google Scholar
• Oram JF, Vaughan AM. ATP-Binding cassette cholesterol transporters and cardiovascular disease. Circ Res 2006;99(10):1031-43
   PubMed Web of Science ®Google Scholar
• Asztalos BF, Tani M, Schaefer EJ. Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol 2011;22(3):176-85
   PubMed Web of Science ®Google Scholar
• Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G. Nanotechnology in cancer therapy. J Drug Target 2013;21(10):904-13
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009;3(1):16-20
   PubMed Web of Science ®Google Scholar
• Sabnis N, Lacko AG. Drug delivery via lipoprotein-based carriers: answering the challenges in systemic therapeutics. Ther Delivery 2012;3(5):599-608
   PubMedGoogle Scholar
• Huynh E, Zheng G. Engineering multifunctional nanoparticles: all-in-one versus one-for-all. Wiley interdisciplinary reviews. Nanomed Nanobiotechnol 2013;5(3):250-65
   Google Scholar
• Ng KK, Lovell JF, Zheng G. Lipoprotein-Inspired Nanoparticles for Cancer Theranostics. Accounts Chem Res 2011;44(10):1105-13
   PubMed Web of Science ®Google Scholar
• Sabnis N, Nair M, Israel M, et al. Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. Int J Nanomed 2012;7:975-83
   PubMed Web of Science ®Google Scholar
• Luthi AJ, Zhang H, Kim D, et al. Tailoring of biomimetic high-density lipoprotein nanostructures changes cholesterol binding and efflux. ACS Nano 2012;6(1):276-85
   PubMed Web of Science ®Google Scholar
• Ng KK, Lovell JF, Vedadi A, et al. Self-Assembled Porphyrin Nanodiscs with Structure-Dependent Activation for Phototherapy and Photodiagnostic Applications. ACS Nano 2013;7(4):3484-90
   PubMed Web of Science ®Google Scholar
• Nakayama T, Butler JS, Sehgal A, et al. Harnessing a physiologic mechanism for siRNA delivery with mimetic lipoprotein particles. Mol Ther 2012;20(8):1582-9
   PubMed Web of Science ®Google Scholar
• Zheng Y, Liu YY, Jin HL, et al. Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles. Theranostics 2013;3(7):477-86
   PubMedGoogle Scholar
• Corbin IR, Ng KK, Ding L, et al. Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers. Nanomedicine 2013;8(6):875-90
   PubMed Web of Science ®Google Scholar
• Rui MJ, Tang HL, Li Y, et al. Recombinant high density lipoprotein nanoparticles for target-specific delivery of siRNA. Pharmaceutical Res 2013;30(5):1203-14
   PubMed Web of Science ®Google Scholar
• Fischer NO, Weilhammer DR, Dunkle A, et al. Evaluation of Nanolipoprotein Particles (NLPs) as an In Vivo Delivery Platform. PloS One 2014;9:3
   Google Scholar
• Wang BL, Yuan Y, Han L, et al. Recombinant lipoproteins reinforce cytotoxicity of doxorubicin to hepatocellular carcinoma. J Drug Target 2014;22(1):76-85
   PubMed Web of Science ®Google Scholar
• Kim Y, Fay F, Cormode DP, et al. Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics. ACS Nano 2013;7(11):9975-83
   PubMedGoogle Scholar
• Bricarello DA, Smilowitz JT, Zivkovic AM, et al. Reconstituted lipoprotein: a versatile class of biologically-inspired nanostructures. ACS Nano 2011;5(1):42-57
   PubMed Web of Science ®Google Scholar
• Sabnis N, Pratap S, Akopova I, et al. Pre-clinical evaluation of rHDL encapsulated retinoids for the treatment of neuroblastoma. Front Pediatr 2013;1:6
   PubMedGoogle Scholar
• Yuan Y, Wang WN, Wang BL, et al. Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier. J Drug Target 2013;21(4):367-74
   PubMed Web of Science ®Google Scholar
• Lin Q, Chen J, Ng KK, et al.Like Nanoparticles. Pharmaceutical Res 2013;31(6):1438-49
   PubMedGoogle Scholar
• Reddy ST, Navab M, Anantharamaiah GM, Fogelman AM. Searching for a successful HDL-based treatment strategy. Biochim Biophys Acta 2014;1841(1):162-7
   PubMedGoogle Scholar
• Knecht TP, Pittman RC. A plasma-membrane pool of cholesteryl esters that may mediate the selective uptake of cholesteryl esters from high-density lipoproteins. Biochim Biophys Acta 1989;1002(3):365-75
   PubMedGoogle Scholar
• Pittman RC, Knecht TP, Rosenbaum MS, Taylor CA. A nonendocytotic mechanism for the selective uptake of high-density lipoprotein-associated cholesterol esters. J Biol Chem 1987;262(6):2443-50
   PubMedGoogle Scholar
• Corbin IR. Ligand-coupled lipoprotein for ovarian cancer-specific drug delivery. Methods Mol Biol 2013;1049:467-80
   PubMedGoogle Scholar
• Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008;108(3):619-26
   PubMed Web of Science ®Google Scholar
• Liadaki KN, Liu T, Xu S, et al. Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. Effect of lipid association and APOA-I mutations on receptor binding. J Biol Chem 2000;275(28):21262-71
   PubMed Web of Science ®Google Scholar
• Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006;116(12):3090-100
   PubMed Web of Science ®Google Scholar
• Jia JT, Xiao Y, Liu JP, et al. Preparation, characterizations, and in vitro metabolic processes of paclitaxel-loaded discoidal recombinant high-density lipoproteins. J Pharm Sci-Us 2012;101(8):2900-8
   PubMedGoogle Scholar
• Wang J, Jia JT, Liu JP, et al. Tumor targeting effects of a novel modified paclitaxel-loaded discoidal mimic high density lipoproteins. Drug Deliv 2013;20(8):356-63
   PubMed Web of Science ®Google Scholar
• Zhang M, Jia J, Liu J, et al. A novel modified paclitaxel-loaded discoidal recombinant high-density lipoproteins: preparation, characterizations and in vivo evaluation. Asian J Pharmaceutical Sci 2013;8(1):11-18
   Google Scholar
• Wagner J, Riwanto M, Besler C, et al. Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs. Arteriosclerosis Thrombosis Vasc Biol 2013;33(6):1392-400
   PubMed Web of Science ®Google Scholar
• Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18(10):997-1006
   PubMed Web of Science ®Google Scholar
• Rayner KJ, Hennessy EJ. Extracellular communication via microRNA: lipid particles have a new message. J Lipid Res 2013;54(5):1174-81
   PubMedGoogle Scholar
• Chen X, Liang H, Zhang J, et al. Horizontal transfer of microRNAs: molecular mechanisms and clinical applications. Protein Cell 2012;3(1):28-37
   PubMed Web of Science ®Google Scholar
• Pritchard CC, Kroh E, Wood B, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prevent Res 2012;5(3):492-7
   PubMed Web of Science ®Google Scholar
• Ding Y, Wang W, Feng MQ, et al. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials 2012;33(34):8893-905
   PubMed Web of Science ®Google Scholar
• Lin QY, Chen J, Jin HL, et al. Efficient systemic delivery of siRNA by using high-density lipoprotein-mimicking peptide lipid nanoparticles. Nanomedicine 2012;7(12):1813-25
   PubMedGoogle Scholar
• Lin Q, Jin CS, Huang H, et al. Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model. Small 2014;10(15):3072-82
   PubMedGoogle Scholar
• Krycer JR, Brown AJ. Cholesterol accumulation in prostate cancer: a classic observation from a modern perspective. Biochim Biophys Acta 2013;1835(2):219-29
   PubMed Web of Science ®Google Scholar
• McMahon KM, Mutharasan RK, Tripathy S, et al. Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett 2011;11(3):1208-14
   PubMed Web of Science ®Google Scholar
• Tripathy S, Vinokour E, McMahon KM, et al. High-density lipoprotein nanoparticles deliver RNAi to endothelial cells to inhibit angiogenesis. Part Part Syst Charact 2014;31(11):1141-50
   PubMed Web of Science ®Google Scholar
• Dong Y, Love KT, Dorkin JR, et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc Natl Acad Sci USA 2014;111(11):3955-60
   PubMed Web of Science ®Google Scholar
• Mahley RW, Huang Y. Apolipoprotein E: from atherosclerosis to Alzheimer’s disease and beyond. Curr Opin Lipidol 1999;10(3):207-17
   PubMedGoogle Scholar
• Van Eck M, Van Dijk KW, Herijgers N, et al. Essential role for the (hepatic) LDL receptor in macrophage apolipoprotein E-induced reduction in serum cholesterol levels and atherosclerosis. Atherosclerosis 2001;154(1):103-12
   PubMedGoogle Scholar
• Mathew S, Murakami T, Nakatsuji H, et al. Exclusive photothermal heat generation by a gadolinium Bis(naphthalocyanine) complex and inclusion into modified high-density lipoprotein nanocarriers for therapeutic applications. ACS Nano 2013;7(10):8908-16
   PubMedGoogle Scholar
• Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290(17):2292-300
   PubMed Web of Science ®Google Scholar
• Easton R, Gille A, D’Andrea D, et al. A multiple ascending dose study of CSL112, an infused formulation of ApoA-I. J Clin Pharmacol 2014;54(3):301-10
   PubMed Web of Science ®Google Scholar
• Keyserling CH, Hunt TL, Klepp HM, et al. CER-001, a synthetic HDL-mimetic, safely mobilizes cholesterol in healthy dyslipidemic volunteers. Circulation 2011;124:21
   Google Scholar
• Zhang Z, Cao W, Jin H, et al. Biomimetic nanocarrier for direct cytosolic drug delivery. Angew Chem 2009;48(48):9171-5
   Google Scholar
• Su F, Grijalva V, Navab K, et al. HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. Mol Cancer Ther 2012;11(6):1311-19
   PubMedGoogle Scholar
• Yang S, Damiano MG, Zhang H, et al. Biomimetic, synthetic HDL nanostructures for lymphoma. Proc Natl Acad Scie USA 2013;110(7):2511-16
   PubMed Web of Science ®Google Scholar
• Zamanian-Daryoush M, Lindner D, Tallant TC, et al. The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol Chem 2013;288(29):21237-52
   PubMedGoogle Scholar
• Rayburn ER, Ezell SJ, Zhang R. Anti-inflammatory agents for cancer therapy. Mol Cell Pharmacol 2009;1(1):29-43
   PubMedGoogle Scholar
• Yang M, Chen J, Cao W, et al. Attenuation of nontargeted cell-kill using a high-density lipoprotein-mimicking peptide–phospholipid nanoscaffold. Nanomedicine 2011;6(4):631-41
   PubMedGoogle Scholar